Published in J Chromatogr B Analyt Technol Biomed Life Sci on August 15, 2012
Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase IκB-α expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription. Antimicrob Agents Chemother (2014) 0.76
A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate - ZMC1. Biomed Chromatogr (2015) 0.75
In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS One (2015) 0.75
Synthesis and Antibacterial Activity of Novel Hydroxy Semicarbazone Derivatives. Iran J Pharm Res (2016) 0.75
Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4'-chlorophenyl)thiazol-2-yl] thiosemicarbazide. Eur J Pharm Sci (1999) 3.59
Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem (1997) 2.01
Key elements of bioanalytical method validation for small molecules. AAPS J (2007) 1.84
Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study. Drug Metab Dispos (2007) 1.72
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol (2003) 1.46
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem (2009) 1.43
Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches. Blood Rev (1995) 1.33
Transcriptional and post-transcriptional regulation of HIV-1 gene expression: role of cellular factors for Tat and Rev. Future Microbiol (2006) 1.32
Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis (1996) 1.30
The role of iron in protozoan and fungal infectious diseases. J Eukaryot Microbiol (1999) 1.28
SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol (2005) 1.25
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol (2010) 1.21
Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology (2009) 1.20
Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci (2000) 1.20
Bone marrow macrophage iron grade and survival of HIV-seropositive patients. AIDS (1999) 1.12
Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11
Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem (2010) 1.05
Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis (2000) 0.99
Phorbol myristate acetate-differentiated THP-1 cells display increased levels of MHC class I and class II mRNA and interferon-gamma-inducible tumoricidal activity. Oncol Res (1993) 0.96
Anti-HIV effect of iron chelators: different mechanisms involved. J Clin Virol (2001) 0.92
Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues. J Med Chem (2007) 0.87
Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. Pharm Res (2002) 0.83
HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.83
An extended-release formulation of desferrioxamine for subcutaneous administration. Drug Deliv (2009) 0.82
The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers. Br J Haematol (1994) 0.81
[Iron homeostasis, a defense mechanism in oxidative stress]. Postepy Biochem (2010) 0.80
Transport kinetics of iron chelators and their chelates in Caco-2 cells. Pharm Res (2006) 0.79
Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT. Anal Bioanal Chem (2010) 0.78
Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.77
An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients. Br J Haematol (1997) 0.77
Iron status and the severity of HIV infection in pregnant women. Clin Infect Dis (2001) 0.77
Treatment of iron overload in adults with continuous parenteral desferrioxamine. Am J Med (1977) 0.77
Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med (2005) 5.78
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet (2002) 4.06
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev (2005) 2.22
Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica (2009) 2.20
Maintaining iron balance in women blood donors of childbearing age: summary of a workshop. Transfusion (2002) 2.15
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem (2006) 2.04
Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. Haematologica (2006) 2.04
Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood (2004) 2.00
Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity. J Biol Inorg Chem (2005) 1.96
The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta (2002) 1.86
Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci (2003) 1.76
Circumstances of death in adult sickle cell disease patients. Am J Hematol (2006) 1.74
Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med (2007) 1.72
The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica (2012) 1.72
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood (2004) 1.67
Iron uptake and metabolism in the new millennium. Trends Cell Biol (2006) 1.66
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
A novel molecular signature for elevated tricuspid regurgitation velocity in sickle cell disease. Am J Respir Crit Care Med (2012) 1.63
A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. J Exp Med (2006) 1.61
Severe vaso-occlusive episodes associated with use of systemic corticosteroids in patients with sickle cell disease. J Natl Med Assoc (2008) 1.51
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis (2006) 1.49
The effect of the host's iron status on tuberculosis. J Infect Dis (2007) 1.49
Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study. Sex Transm Infect (2012) 1.48
N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One (2013) 1.46
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem (2009) 1.43
Growth arrest and DNA damage-45 alpha (GADD45alpha). Int J Biochem Cell Biol (2008) 1.43
The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol (2002) 1.40
Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA (2011) 1.38
Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol (2003) 1.38
The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem (2012) 1.38
Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A (2009) 1.31
Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. Inorg Chem (2006) 1.30
Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res (2003) 1.30
Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood (2002) 1.29
Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis (2002) 1.28
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res (2006) 1.28
Pulmonary hypertension and NO in sickle cell. Blood (2010) 1.28
Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res (2011) 1.28
Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol (2013) 1.25
Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology (2006) 1.25
Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol (2008) 1.24
The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci U S A (2008) 1.22
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol (2010) 1.21
Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol (2010) 1.21
Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol (2008) 1.19
Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood (2009) 1.18
Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde. Acta Crystallogr C (2003) 1.17
The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis (2011) 1.17
Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood (2009) 1.16
Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management. Am J Hematol (2008) 1.16
Novel chelators for cancer treatment: where are we now? Antioxid Redox Signal (2012) 1.16
Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood (2006) 1.15
HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem (2002) 1.15
Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. Br J Haematol (2013) 1.14
Protein phosphatase-1 dephosphorylates the C-terminal domain of RNA polymerase-II. J Biol Chem (2002) 1.14
Dephosphorylation of CDK9 by protein phosphatase 2A and protein phosphatase-1 in Tat-activated HIV-1 transcription. Retrovirology (2005) 1.13
Tuning cell cycle regulation with an iron key. Cell Cycle (2007) 1.13
The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J (2009) 1.12
Nuclear protein phosphatase-1 regulates HIV-1 transcription. J Biol Chem (2003) 1.12
Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test (2005) 1.12
Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. Br J Haematol (2009) 1.12
Serum ferritin and transferrin saturation in Asians and Pacific Islanders. Arch Intern Med (2007) 1.12
Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. Int J Biochem Cell Biol (2004) 1.11
Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11
Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol (2011) 1.11
Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. Am J Hematol (2012) 1.10
Nuclear targeting of protein phosphatase-1 by HIV-1 Tat protein. J Biol Chem (2005) 1.10
Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chem Res Toxicol (2007) 1.10
The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid Redox Signal (2012) 1.09
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol (2012) 1.08